Pikeville Medical Center to Pay $4.39 Million to Resolve Alleged Controlled Substance Act Violations That Allowed Drug Diversion | USAO-EDKY

LEXINGTON, Ky. — The United States Attorney’s Office for the Japanese District of Kentucky announced that Pikeville Clinical Heart (“PMC”) has agreed to pay out the United States $4,394,600 in civil penalties, to resolve allegations that its violations of the Controlled Substances Act’s (“CSA”) recordkeeping provisions resulted in considerable diversion of hazardous opioids from its pharmacy.  The settlement is a single of the nation’s largest relating to CSA recordkeeping violations involving allegations of drug diversion at a medical center. The settlement is the 3rd-greatest civil penalty ever obtained from a clinic procedure below the CSA.

As a registrant with the U.S. Drug Enforcement Administration (“DEA”), PMC had specific recordkeeping obligations, which integrated preserving finish and accurate data of every single managed compound acquired, dispensed, and disposed.  DEA has the authority to inspect the documents of registrants like PMC, to validate that their records are comprehensive, accurate, and in compliance with the CSA.

In settlement paperwork, the Governing administration contends that about a two-calendar year period, PMC violated various provisions of the CSA relating to recordkeeping, which includes by failing to keep finish and exact inventories and dispensing documents for Timetable II controlled substances.  The Government alleges that as a final result of these failures, a PMC pharmacy technician was able to divert more than 60,000 dosage units of oxycodone, hydrocodone, and methadone from PMC’s narcotics vault and Pyxis MedStations, from January 1, 2016, via September 7, 2018.  The managed substances diverted from PMC in the long run were being dispersed by the pharmacy technician’s partner to the group.  Both the PMC pharmacy technician and her partner have pled guilty to violating 21 U.S.C. § 846, conspiracy to distribute Timetable II controlled substances, in the make a difference of United States v. Perry et al., 7:20-cr-12. 

“As the opioid crisis continues to plague communities in Kentucky, hospitals like PMC have a obligation and significant purpose to enjoy.  They ought to make sure that managed substances are thoroughly tracked and protected towards theft and reduction, so that these medication are not diverted for unlawful utilizes,” mentioned Carlton S. Shier, IV, United States Attorney for the Jap District of Kentucky.  “My workplace will go on to request acceptable civil penalties from healthcare vendors who are careless with their recordkeeping and fall short to offer efficient safeguards against drug diversion.”

“All DEA registrants, to include hospitals and healthcare vendors, are obligated to adhere to the rigorous report-trying to keep prerequisites outlined in the Controlled Substances Act failure to do so normally sales opportunities to the diversion of controlled substances,” mentioned Particular Agent in Demand Todd Scott, head of the Drug Enforcement Administration’s Louisville Division.  “The measurement of this good reveals how critical this problem is.  With any luck ,, Pikeville Healthcare Centre will do a far better position in the upcoming with their report preserving and the ensuing hurt inflicted on the local community can be reversed.”

As part of the settlement, PMC has entered into a three-12 months Memorandum of Arrangement with DEA, which prescribes the hospital’s drug-managing responsibilities going ahead. These steps consist of: 

• Allowing DEA personnel to enter its registered spot at any time through normal company several hours with out an administrative inspection warrant, and with no prior notification to PMC, to validate compliance with the Memorandum of Arrangement
• Conducting an stock of find managed substances each and every six months and delivering the effects to DEA
• Investigating and documenting any concerns about diversion, employee theft, or significant decline of managed substances
• Reporting suspicious controlled compound incidents to DEA on a quarterly basis and
• Providing necessary schooling on federal legal guidelines and laws pertaining to managed substances for all personnel and deal staff who have accessibility to managed substances.

PMC cooperated with the DEA’s investigation and self-documented the diversion.  As identified in the Memorandum of Agreement, PMC took considerable measures to tackle its deficiencies in its dealing with of controlled substances ahead of the settlement was entered.

A most important aim of the CSA is controlling illegitimate targeted traffic in controlled substances.  To avoid the diversion of controlled substances, the CSA regulates individuals and entities that manufacture, distribute, and dispense controlled substances.  The Government’s investigation and resolution of this make any difference illustrates its continued emphasis on combating the prescription opioid disaster by guaranteeing that opioids are not diverted.  Any one with fears about prescription drug diversion can report them to the DEA, by publishing a suggestion at https://www.dea.gov/post-tip.

The scenario was investigated by the Drug Enforcement Administration’s London Resident Place of work Diversion Group, with assistance from the Kentucky Board of Pharmacy, and taken care of by the U.S. Attorney’s Office’s Affirmative Civil Enforcement part, which include Assistant U.S. Lawyers Meghan Stubblebine and Mary Melton.  The claims fixed by the settlement are allegations only, and there has been no willpower of liability.

-Stop-